Jonathan Lim, Co-Lead of The Manchester Immuno-Oncology Network (MION) and Lead of The Christie International Fellowship Program for Medical Oncology at The Christie NHS Foundation Trust, shared a post on LinkedIn by The Christie NHS Foundation Trust, adding:
“It truly takes a village to tackle complex problems. I feel genuinely grateful to work alongside such an inspiring group of physicians, nurses, AHPs, scientists, and industry innovators, all united by a shared commitment to our patients.
This photo is from our RISE Manchester launch meeting (we still need a full team photo!) – We’re ready to roll up our sleeves and get going!”
Quoting The Christie NHS Foundation Trust’s post:
“CAR-T therapy is a type of immunotherapy that is transforming survival prospects for certain patients with blood cancers like lymphoma and leukaemia.
However, many experience severe immune system overreactions, including cytokine release syndrome (CRS), which can be potentially life-threatening.
Dr Jonathan Lim and his team at The Christie, Cancer Research UK Manchester Institute, and The University of Manchester are working to change this. Building on 30 years of worldwide research, the RISE Manchester study aims to help patients with cancer better tolerate cutting-edge immunotherapy treatments like CAR-T.
The £8m programme, which aims to recruit up to 100 patients over 5 years, has secured £3.4 million from the Medical Research Council, along with funding from industry partners.
Dr Lim says: ‘Funding of this scale is rare, and we’re very grateful for the opportunity. It reflects both the complexity of the challenge and the shared hope that this work can genuinely improve patients’ lives.’
‘RISE brings together experts from across Manchester to understand how powerful new cancer immunotherapies work, and why they sometimes cause serious side effects. Our ambition is to position the UK as a global leader in research focused on the safe delivery of cell therapies.’
More.”
More posts featuring Jonathan Lim.